Product Description and Product Data
This is an all-inclusive cell-based luciferase reporter assay kit targeting the the Human G-Protein-Coupled Receptor 39 Reporter Assay System (GPR39). INDIGO’s GPR39 reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the GPR39. In addition to GPR39 Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against GPR39. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.
Features
Clear, Reproducible Results
- All-Inclusive Assay Systems
- Exceptional Cell Viability Post-Thaw
- Consistent Results Lot to Lot
Product Specifications
| Target Type | GPCR | ||
| Species | Human | ||
| Receptor Form | Hybrid | ||
| Assay Mode | Activation, Inhibition | ||
| Kit Components |
| ||
| Shelf Life | 6 months | ||
| Shipping Requirements | Dry Ice | ||
| Storage temperature | -80C |
Data

Target Background
This assay utilizes proprietary human cells that provide constitutive expression of the Human G-Protein-Coupled Receptor 39 (GPR39).
G-protein-coupled receptors (GPCRs) play a pivotal role in mediating responses to various hormones, neurotransmitters, and external stimuli, making them essential therapeutic targets for multiple conditions. GPR39, an orphan GPCR, is widely expressed in diverse tissues such as the pancreas, gastrointestinal tract, liver, kidneys, skin, adipose tissue, and brain.
GPR39 is associated with neurodegenerative diseases such as Alzheimer’s, dementia, epilepsy and depression. In addition, recent evidence has highlighted the role of GPR39 in metabolic and endocrine diseases such as diabetes and obesity. Consequently, GPR39 commands considerable interest in therapeutics development.
Product Documentation
Citations
Also available as a service